

# Validation of maternal cardiac output trending with impedance cardiography against transthoracic Doppler echocardiography in healthy pregnant women.

Published: 25-07-2017

Last updated: 15-04-2024

ICG allows continuous, non-invasive monitoring of the CO. ICG is a method that detects changes in thoracic electrical bioimpedance between simple skin electrodes, together with a conventional ECG. To estimate CO, it uses complex algorithms based on...

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruiting
<b>Health condition type</b>	Maternal complications of pregnancy
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON45637

### Source

ToetsingOnline

### Brief title

ICG-trending

### Condition

- Maternal complications of pregnancy

### Synonym

healthy pregnancy

### Research involving

Human

## Sponsors and support

**Primary sponsor:** Erasmus MC, Universitair Medisch Centrum Rotterdam

**Source(s) of monetary or material Support:** Ministerie van OC&W

## Intervention

**Keyword:** Impedance cardiography, Pregnancy, Transthoracic echocardiography, Validation

## Outcome measures

### Primary outcome

Validation of ICG for the assessment of CO in trending ability (relative  $\Delta$ CO)

during pregnancy using TTE, using the 4-quadrant plot, and calculating the

concordance rate, angular bias and radial limits of agreement

- Hypothesis: ICG accurately allows CO trending during pregnancy as compared to TTE.

### Secondary outcome

Assessing agreement between ICG and TTE for individual CO measurements in pregnant women.

## Study description

### Background summary

During healthy pregnancy, the maternal cardiovascular system changes to contribute to optimal growth and development of the foetus and help to protect the mother from risks. Major hemodynamic changes induced by pregnancy include increase of the maternal cardiac output (CO) above non-pregnant levels. CO is a functional parameter, reflecting the total demand placed on the cardiovascular system. CO is defined as the volume of blood pumped into the aorta per unit time and is calculated as the product of stroke volume (SV) and heart rate (HR). Direct and indirect causes of maternal mortality and morbidity like preeclampsia and haemorrhage and cardiac diseases, have been associated with substantial changes in CO. Nowadays, monitoring maternal cardiovascular function is limited to indirect parameters of maternal cardiovascular function

including heart rate and blood pressure. Measuring the CO could be a major help in directing management and treatment in pregnant woman with cardiac pathology and in pregnancy complications.

Invasive techniques such as Intermittent Bolus Pulmonary Artery Thermodilution, continue to be the gold standard to measure CO. Since this method requires right heart catheterization with a pulmonary artery catheter, it is associated with a variety of complications to the participant. This method is controversial on account of its invasiveness and with inherent risks. A non-invasive continuous measurement could be of major value.

Transthoracic echocardiography (TTE) is a clinically established non-invasive diagnostic method that provides assessment of cardiac structure and function. CO can be calculated with two-dimensional pulsed wave Doppler as the product of the cross-sectional area and left ventricular outflow tract velocity time integral (LVOT VTI). This method has been validated to measure CO against invasive techniques in and outside pregnancy. However, this technique has its limitations. TTE is dependent on the operator's skill in acquiring images taking correct measurements and continuous assessment is time consuming.

## **Study objective**

ICG allows continuous, non-invasive monitoring of the CO. ICG is a method that detects changes in thoracic electrical bioimpedance between simple skin electrodes, together with a conventional ECG. To estimate CO, it uses complex algorithms based on assumptions regarding the thoracic dimensions and shape to convert changes in thoracic impedance into volume changes. In theory, the specific pattern of major physiological adaptations of the pregnant body could influence these assumptions. Physioflow, the device we will use for ICG, was designed to monitor performing athletes, and is thereby equipped with a high signal stability. On that account it can be of value in woman during both pregnancy and labour, which puts an enormous strain on the maternal cardiovascular function. Although there have been numerous validation studies of methods of continuous CO measurement, the majority evaluated the measurement of the actual value of CO. Less than one-fifth of the studies addressed CO trending. Although the accuracy of ICG for absolute CO values appears moderately convincing, it is generally agreed to be capable of trend analysis. However, this technique has not been validated in pregnancy.

As a result, further validation of ICG trending ability during pregnancy is required. We aim to examine the agreement in CO trending between ICG and the clinically established method of TTE in a cohort of healthy pregnant woman. To induce changes in the CO during our measurements, we will submit pregnant women to a limited exercise.

## **Study design**

A prospective comparative study with non-invasive techniques will be performed in order to compare CO trending by ICG with TTE. This trial will be conducted at a tertiary care center, Erasmus University Medical Center Rotterdam. We propose a maximum duration of the study of six months.

### **Study burden and risks**

Burden associated with participation exists of one investigation for an estimated time of 30 minutes. The patients will be examined with ICG and TTE in the left lateral decubitus position in all measurements. After the baseline measurement, participants will exercise on a home trainer until their heart rate rises up to 70% of their maximum heart rate. When this limit is reached, participants will exercise at this heart rate for 1 minute. Subsequently the second measurement takes place. When the heart rate decreases to <20% of the maximum heart rate, the last measurement will be performed. Moreover, maternal data will be collected during participation, including the blood pressure and measured height and weight to determine current BMI. Self-reported age, weight prior to conception, gravidity and parity will be obtained. There is no risk associated with participation for mother and foetus. There is no individual benefit for participants.

## **Contacts**

### **Public**

Erasmus MC, Universitair Medisch Centrum Rotterdam

Wytemaweg 80  
Rotterdam 3015CN  
NL

### **Scientific**

Erasmus MC, Universitair Medisch Centrum Rotterdam

Wytemaweg 80  
Rotterdam 3015CN  
NL

## **Trial sites**

### **Listed location countries**

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

Women without history or symptoms of cardiovascular diseases with a normal, uncomplicated singleton pregnancy, aged  $\geq 18$  years with informed consent.

### Exclusion criteria

- Any known pre-existing cardiac, hypertensive or renal disease
- Any contraindication for exercise
- Multiple pregnancy
- Labouring pregnant women
- Not regularly attending scheduled obstetric appointments

## Study design

### Design

**Study type:** Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruiting

Start date (anticipated): 25-07-2017

Enrollment: 43

Type: Actual

## Medical products/devices used

Generic name: impedance cardiography; Physioflow  
Registration: Yes - CE intended use

## Ethics review

Approved WMO  
Date: 25-07-2017  
Application type: First submission  
Review commission: METC Erasmus MC, Universitair Medisch Centrum Rotterdam (Rotterdam)

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
CCMO	NL58545.078.16